Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Male hypogonadism Age: Adult |
Dose: Intramuscular – 50-400 mg Frequency: every 2-4 weeks Note: Or an initial dose of 250 mg every 2-3 weeks followed by a maintenance dose every 3-6 weeks |
|
Indication: Inoperable metastatic breast cancer Age: Adult |
Dose: Intramuscular – 200-400 mg Frequency: every 2-4 weeks Note: As enanthate |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hypogonadism Age: less than 12 years |
Dose: Safety and efficacy not established Note: Safety and efficacy not established |
|
Indication: Hypogonadism Age: greater than 12 years |
Dose: Intramuscular Injection – 50-400 mg Frequency: every 2-4 weeks |
Administration
- Deep IM injection in gluteal muscle
- Rotate injection sites
Side Effect
- Fluid and electrolyte retention
- increased vascularity of the skin
- hypercalcaemia
- impaired glucose tolerance
- increased bone growth and skeletal weight
- increase LDL cholesterol
- increase haematocrit and fibrinolytic activity
- headache
- depression and GI bleeding
- Males spermatogenesis suppression
- priapism
- gynaecomastia
- prostatic hyperplasia and accelerate growth of malignant prostate neoplasms
- Females suppression of lactation
- ovarian activity and menstruation
- virilization
- clitoris hypertrophy
- increased libido
- oily skin
- acne
- hirsutism
- male pattern baldness
- Children Closure of the epiphyses and stop linear growth in early puberty
- symptoms of virilisation
- Precocious sexual development
- increased frequency of erection in boys
- and clitoral enlargement in girls
- IM urticaria
- inflammation at Injection site
- postinjection induration
- furunculosis
- Peliosis hepatis
- liver toxicity
- malignant neoplasm
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Ciclosporine, Antidiabetics (Metformin, Glibenclamide, Glimepiride, Sitagliptin, Pioglitazone, Rosiglitazone, Empagliflozin), Thyroxine, Anticoagulants (Warfarin, Heparin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban)
|
Enhanced activities
|
|
Neuromuscular blockers
|
May cause resistance to effects
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypercalcemia
|
Risk of calcium imbalance
|
|
Male Breast/Prostate Cancer
|
May stimulate cancer growth
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.